Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Voelter, Verena | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Ryoo, Hun-Mo | - |
dc.contributor.author | Kim, Yang Soo | - |
dc.contributor.author | Moon, Joon Ho | - |
dc.contributor.author | Park, Seong Kyu | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Jo, Deog-Yeon | - |
dc.contributor.author | Jun, Hyun Jung | - |
dc.contributor.author | Kim, Ki-Hwan | - |
dc.contributor.author | Lee, Jeong-Ok | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.date.available | 2020-02-28T18:43:30Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12922 | - |
dc.description.abstract | We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.subject | REFRACTORY MULTIPLE-MYELOMA | - |
dc.subject | IMPAIRED RENAL-FUNCTION | - |
dc.subject | PLUS DEXAMETHASONE | - |
dc.subject | THERAPY | - |
dc.subject | THALIDOMIDE | - |
dc.subject | EFFICACY | - |
dc.subject | CYTOGENETICS | - |
dc.subject | COMBINATION | - |
dc.subject | MECHANISM | - |
dc.subject | OUTCOMES | - |
dc.title | Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000329093200013 | - |
dc.identifier.doi | 10.1007/s00277-013-1893-z | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.93, no.1, pp.113 - 121 | - |
dc.identifier.scopusid | 2-s2.0-84891838863 | - |
dc.citation.endPage | 121 | - |
dc.citation.startPage | 113 | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 93 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Lenalidomide | - |
dc.subject.keywordAuthor | Relapsed myeloma | - |
dc.subject.keywordAuthor | Korean | - |
dc.subject.keywordPlus | REFRACTORY MULTIPLE-MYELOMA | - |
dc.subject.keywordPlus | IMPAIRED RENAL-FUNCTION | - |
dc.subject.keywordPlus | PLUS DEXAMETHASONE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | THALIDOMIDE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | CYTOGENETICS | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | MECHANISM | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.